Frazier Life Sciences led a $187m Series A round in Callio Therapeutics.

Frazier Life Sciences, a US-based venture capital firm, led a $187m Series A round in Callio Therapeutics, a US-based biotechnology company specializing in the development of multi-payload antibody-drug conjugates, with participation from Jeito Capital, Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. "The multi-payload ADCs being developed at Callio Therapeutics have the potential to address large unmet medical needs by overcoming many of the limitations of existing ADCs. With the expertise of the Callio Therapeutics team, together with access to the innovative multi-payload ADC technology, we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy," Adam Simpson, Frazier Life Sciences Venture Partner.